Patents by Inventor Tina Vilsboll

Tina Vilsboll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 as a diagnostic test to determine ?-cell function and the presence of the condition of IGT and type-II diabetes
    Patent number: 6884579
    Abstract: Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in ?-cell stimulatory tests in order to test ?-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: April 26, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Jens J. Holst, Tina Vilsboll
  • GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes
    Publication number: 20050009127
    Abstract: Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in ?-cell stimulatory tests in order to test ?-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.
    Type: Application
    Filed: August 2, 2004
    Publication date: January 13, 2005
    Inventors: J.J. Holst, Tina Vilsboll
  • GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes
    Publication number: 20030091507
    Abstract: Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in &bgr;-cell stimulatory tests in order to test &bgr;-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.
    Type: Application
    Filed: October 26, 2001
    Publication date: May 15, 2003
    Inventors: J. J. Holst, Tina Vilsboll
  • GLP-1 as a diagnostic test to determine &bgr;-cell function and the presence of the condition of IGT and type II diabetes
    Patent number: 6344180
    Abstract: Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in &bgr;-cell stimulatory tests in order to test &bgr;-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: February 5, 2002
    Assignee: BioNebraska, Inc.
    Inventors: J. J. Holst, Tina Vilsboll